Women with type 2 diabetes mellitus (T2DM) are at a greater risk of developing and dying from breast cancer than women without T2DM. Insulin resistance and hyperinsulinemia underlie the pathogenesis of T2DM.
Introduction
Women with type 2 diabetes mellitus (T2DM) and the metabolic syndrome (a syndrome of insulin resistance and hyperinsulinemia) are at a greater risk of developing and dying from breast cancer than women without these conditions (Agnoli et al., 2010; Patterson et al., 2010; Peairs et al., 2011) . Even in the absence of T2DM or the metabolic syndrome, having a fasting insulin level that lies in the upper quartile of the normal population range has been reported to increase the risk of breast cancer recurrence and death, in women with early stage breast cancer (Goodwin et al., 2002) . In human breast cancer, insulin receptor (IR) content is frequently increased (Papa et al., 1990) , and therefore in the setting of insulin resistance and hyperinsulinemia, activation of the IR and its downstream signaling pathways may promote breast cancer growth. In our previous studies, we have employed the female MKR mouse to investigate the mechanisms underlying the link between hyperinsulinemia and breast cancer. The female MKR mouse has significant insulin resistance and hyperinsulinemia with mild glucose intolerance . Our previous studies have demonstrated that female MKR mice develop larger mammary tumors than wild type (WT) mice. The IR/insulin-like growth factor-1 receptor/phosphatidylinositol 3-kinase (PI3K)/Akt/mTOR pathway was the main signaling pathway that demonstrated increased activation in tumors from the MKR mice .
The PI3K/Akt/mTOR signaling pathway and its activation by IRb/IGF-IRb phosphorylation has recently received intense investigation with the emergence of resistance to current chemotherapeutic agents, and the identification of mutations that lead to dysregulation of this pathway (Junttila et al., 2009; Creighton et al., 2010; Lo´pez-Knowles et al., 2010) . PI3K consists of two subunits, a p110 catalytic subunit and its regulatory p85 subunit. After receptor phosphorylation, binding of adaptor proteins, such as insulin receptor substrate-1, to the p85 subunit releases the p110 catalytic subunit from its inhibitory regulation and allows for the phosphorylation of phosphatidylinositol-4,5-bisphosphate to generate phosphatidylinositol-3,4,5-triphosphate . Phosphatidylinositol-3,4,5-triphosphate phosphorylates Akt leading to the activation of a plethora of signaling molecules. Multiple gene mutations can increase signaling through the PI3K/Akt/mTOR pathway in breast cancers, for example, loss of activity of the tumor suppressor gene phosphatase and tensin homolog deleted on chromosome ten, amino-acid substitutions in PI3KCA (encoding the p110a catalytic subunit of PI3K), overexpression of human epidermal growth factor receptor-2 (HER-2) and mutations in Akt. In cell lines, increased PI3K signaling has been shown to confer resistance to the monoclonal antibody trastuzumab that is directed against HER-2, and is used to treat HER-2 receptor-positive breast cancers in women (O'Brien et al., 2010) . Additionally, in estrogen receptor (ER)-positive breast cancer cells, PI3K activity is associated with decreased expression of ER and ER target genes. This decreased ER expression in ER-positive tumors is associated with resistance to hormonal therapy (Creighton et al., 2010) . Therefore, insulin resistance and endogenous hyperinsulinemia, leading to increased activation of the PI3K signaling pathway, may result in resistance to HER-2 and ER targeted therapy, and so may be an important therapeutic target in individuals with breast cancer who have increased insulin levels, the metabolic syndrome or T2DM.
However, two particular concerns have arisen with regard to inhibiting the PI3K/Akt/mTOR pathway. First, that inhibition of PI3K signaling in HER-2-overexpressing tumors will lead to a compensatory increase in Erk1/2 signaling, as was recently described with the PI3K inhibitors, GDC-0941 and PIK-90 in cell lines and the dual PI3K/mTOR inhibitor, BEZ235 in xenografts inoculated into mice (Serra et al., 2011) . Second, that inhibiting PI3K may result in significant hyperglycemia. We have previously demonstrated that inhibiting mTOR with rapamycin led to increased glucose and triglyceride levels in MKR mice, but did not lead to a further increase in the already elevated plasma insulin levels and did not affect Ser 473 phosphorylation of Akt in tumors . PI3K inhibition would be expected to lead to different metabolic effects than rapamycin because of the effects of PI3K inhibition on the phosphorylation of Akt and on atypical isoforms of protein kinase C z. Both Akt and atypical isoforms of protein kinase C z are important for insulin-mediated glucose uptake in muscle and adipose tissue by glucose transporter 4 (GLUT4) (Kohn et al., 1996; Liu et al., 2006) . Therefore, we aimed to examine the effect of inhibiting PI3K on tumor progression and metabolic parameters in a mouse model of hyperinsulinemia. In this study we inhibited PI3K with the oral pan-class I inhibitor of PI3K, NVP-BKM120, and evaluated the growth of mammary tumor orthografts in the hyperinsulinemic MKR mouse. We examined the PI3K/Akt/ mTOR signaling pathway to determine whether this inhibitor could adequately block signaling in tumors from the MKR mouse, where the activity of this pathway is known to be increased. We also studied the phosphorylation of Erk1/2 to determine whether inhibition of PI3K led to a compensatory increase in Erk1/2 signaling in the MKR mouse. Additionally, we examined the effects of inhibiting PI3K on metabolic parameters, including glucose, insulin and triglyceride levels. Finally, in view of our previous study demonstrating that inhibiting mTOR with rapamycin led to hyperglycemia in the MKR mouse, but reduced tumor growth , we were interested to know whether inhibiting both PI3K and mTOR with the targeted dual inhibitor, NVP-BEZ235 would lead to an additional suppression of tumor growth, and whether it would affect insulin and glucose levels in the MKR mouse. We also aimed to discover whether the dual PI3K/mTOR inhibitor would lead to a compensatory increase in Erk1/2 signaling in this model, similar to the results from animal models without insulin resistance (Serra et al., 2011) .
Results

Inhibiting PI3K reduces tumor growth in the MKR mouse
The MKR mouse is a nonobese animal model of type 2 diabetes. The female MKR mouse has marked hyperinsulinemia, but only mild dysglycemia. We have previously demonstrated that after orthotopic inoculation of Met-1 and MCNeuA cells into the fourth mammary fat pad, MKR mice develop larger tumors than WT mice . Met-1 mammary tumor cells were initially derived from MMTV-Polyoma Virus middle T antigen transgenic mice (Borowsky et al., 2005) and MCNeuA mammary tumor cells were derived from MMTV-Neu transgenic mice, the rodent equivalent of the human ErbB2 or HER-2 gene (Campbell et al., 2002) . Met-1 cells have a high proliferation rate and have a mesenchymal phenotype. MCNeuA cells have an epithelial phenotype and have a low proliferation rate.
We orthotopically inoculated MKR mice and WT mice with Met-1 and MCNeuA cells, as previously described . Cells were injected 1 week apart, to allow for the lower proliferation rate of the MCNeuA cells. At 2 weeks after injection of the Met-1 cells and 3 weeks after injection of MCNeuA cells, the MKR and WT mice were divided into two treatment groups that were matched for respective tumor size (Figures 1a and c) . Mice were treated with NVP-BKM120 (50 mg/kg) by oral gavage, or the same volume of the vehicle. Treatment continued for 2 weeks with interval measurement of tumor growth over that time and measurement of tumor weight at the end of the study. The volumes of both Met-1 and MCNeuA tumors were significantly lower in the MKR mice treated with NVP-BKM120, compared with the MKR vehicle-treated group (Figures 1a and c) . Similarly, the weights of MCNeuA and Met-1 tumors were significantly reduced in the MKR group treated with NVP-BKM120, and the MCNeuA tumor weights were also significantly reduced in the WT group (Figures 1b and d) . Therefore, in the insulin resistant, hyperinsulinemic mouse, inhibiting PI3K with NVP-BKM120 decreases the growth of mammary tumors known to have increased activation of the PI3K/Akt/mTOR signaling pathway. and Akt (Ser473) in Met-1 and MCNeuA tumors inoculated into MKR mice, compared with those injected into WT FVB/N mice . No change was seen in phosphorylation of Akt (Ser473) in response to treatment with the mTOR inhibitor rapamycin . In this study, we again observed a statistically significant increase in Akt 
Inhibiting PI3K led to reduced proliferation in Met-1 tumor orthografts in MKR mice
We have previously demonstrated increased proliferation in the Met-1 tumors in MKR mice by evaluation of protein extracts for proliferating cell nuclear antigen on western blot . To examine whether this increase in S phase growth was inhibited with NVP-BKM120, the mice were injected with 5-bromo-2 0 - PI3K blockade reduces insulin induced tumor growth EJ Gallagher et al deoxyuridine (BrdU) 2 h before tumor tissue collection. The percent of cells that stained positive for BrdU in the Met-1 tumors was evaluated by immunofluorescence. We found a significantly higher percent of BrdU-positive cells in the vehicle-treated MKR mice (9.9±0.76%), compared with vehicle-treated WT mice (7.8 ± 0.35%) (Figure 3a) . Treatment of the MKR mice with NVP-BKM120 led to a significantly lower percent of BrdU-positive cells (5.8±1.13%), compared with vehicle-treated MKR mice (P ¼ 0.001). The percent of BrdU-positive cells in the Met-1 tumors from the MKR mice treated with NVP-BKM120 was comparable to the percent of BrdU-positive cells in the WT NVP-BKM120-treated group (5.8 ± 0.63%).
Therefore, in the MKR mice, inhibiting PI3K with NVP-BKM120 attenuated the increased cellular proliferation in Met-1 tumors from the MKR mice (Figure 3b ). Western blot analysis of apoptosis, using the antibody to the anti-apoptotic protein Bcl-2 revealed decreased levels of Bcl-2 when normalized to b actin, in the MKR vehicle-treated group, compared with the MKR NVP-BKM120-treated group (data not shown).
Mice treated with NVP-BKM120 developed metabolic derangements Before treatment, MKR mice had mildly elevated blood glucose levels (10.6 ± 0.5 mmol/l), compared with WT mice Figure 2 Treatment with NVP-BKM120 reduced serine phosphorylation of Akt and S6rp in MCNeuA and Met-1 tumors treated with NVP-BKM120. Protein extracts from MCNeuA and Met-1 tumors from WT and MKR mice were size fractionated and immunoblotted against phospho (Ser473) and total Akt, phospho (Ser235/236) and total S6rp, and phospho (Thr202/Tyr204) and total Erk1/2 (a, b, g, h) . Representative western blot analyses are displayed for MCNeuA tumors (a, g) and Met-1 tumors (b, h). c-f, i, j) display the densitometric analyses of phosphorylated Akt normalized to total Akt, phosphorylated S6rp normalized to total S6rp levels and phosphorylated Erk1/2 normalized to total Erk1/2 for MCNeuA and Met-1 tumors. Data in (c-f, i, j) are presented as a fold change in the mean ( ± s.e.m.) of each group compared with the WT vehicle-treated group. *Po0.05 between groups. BKM, NVP-BKM120 treated; V, vehicle treated.
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EJ Gallagher et al (7.2 ± 0.2 mmol/l) (Figure 4a ). Following 2 weeks of treatment, significant hyperglycemia developed in the WT and MKR groups treated with NVP-BKM120 (Figure 4) , and was demonstrated during the glucose tolerance test (Figure 4b ). Plasma insulin levels revealed that WT and MKR mice treated with NVP-BKM120 had significant hyperinsulinemia, compared with the vehicletreated mice, with the levels for the WT mice increasing at an Bseven fold and for MKR mice rising >ten fold (Figure 4c ). Triglyceride levels also increased in the MKR mice treated with NVP-BKM120 to a modest (1.5-fold increase) but significant degree, although no increase was seen in the WT mice (Figure 4d ).
Comparison of PI3K inhibition alone with the PI3K and mTOR dual inhibitor NVP-BEZ235
We were interested to discover the effects of inhibiting both PI3K and mTOR on the tumor growth and glucose control in the MKR mice. Our previous studies had demonstrated that the mTOR inhibitor rapamycin reduced tumor growth, but increased glucose levels in the MKR mice, whereas our current study demonstrated that inhibiting PI3K with NVP-BKM120 also reduced tumor growth, but led to more severe hyperglycemia and hyperinsulinemia than rapamycin. We therefore speculated that inhibiting both PI3K and mTOR could have a synergistic effect on the reduction in tumor growth. Analogous to the study with NVP-BKM120, we inoculated the fourth mammary fat pad of WT and MKR mice with Met-1 and MCNeuA cells, and divided them into treatment groups, with the dual PI3K/mTOR inhibitor NVP-BEZ235 (40 mg tosylate salt/kg body weight) or the vehicle (10% NMP: 90% PEG300), by daily gavage for 2 weeks. Before treatment began, the groups were matched for tumor size, and serial measurements were taken during the study to calculate the tumor volume. At the end of the study tumor weights were also recorded. Proteins from the MCNeuA and Met-1 tumors were isolated, as previously described 
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and again phosphorylation of the Akt, S6rp and Erk1/2 were examined relative to their total protein levels. The volumes of both MCNeuA and Met-1 tumors were again significantly decreased in the MKR mice treated with the dual PI3K/mTOR inhibitor NVP-BEZ235 (Figures 5a and b) ; tumor weight was not significantly different in the treatment groups, as there was a wide distribution in the tumor weights because of variable areas of necrosis (Figures 5c and d) . Analysis of tumor proteins revealed a significant decrease in phosphorylation of Akt and S6rp in the MKR and WT NVP-BEZ235-treated group, compared with the vehicle-treated groups (Figures 5e-g and i) . In contrast to the PI3K inhibitor NVP-BKM120, an increased Erk1/2 phosphorylation was seen in the Met-1 tumors from MKR mice treated with NVP-BEZ235, when compared with those treated with the vehicle (Figure 5j ). Glucose intolerance and hyperinsulinemia developed in the MKR mice treated with NVP-BEZ235 (Figures 6a and b) , but the degree of glucose intolerance and hyperinsulinemia was not as great as with NVP-BKM120 treatment. No significant hyperinsulinemia developed in the WT group treated with NVP-BEZ235, compared with controls ( Figure 6b) .
Discussion
Our results demonstrate that in the MKR mouse model of insulin resistance, inhibiting PI3K with NVP- 
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EJ Gallagher et al BKM120 decreased the growth of tumor orthografts known to have increased activation of the PI3K/Akt/ mTOR pathway in the hyperinsulinemic mouse. In the MKR mouse, inhibiting PI3K alone reduced Akt phosphorylation and did not lead to a compensatory increase in Erk1/2 signaling. In contrast to our study of rapamycin, inhibiting both PI3K and mTOR led to a reduction in Akt phosphorylation as well as a decrease PI3K blockade reduces insulin induced tumor growth EJ Gallagher et al in S6rp phosphorylation; however, increased activation of Erk1/2 signaling in Met-1 tumors from the MKR mouse treated with NVP-BEZ235 was seen. These results are partially consistent with the findings of other groups who reported that inhibition of PI3K alone (with GDC-0941 and PIK90), or in combination with mTOR (NVP-BEZ235) led to a compensatory increase in Erk1/2 signaling in tumor xenografts (Serra et al., 2011) . Notably, the PI3K inhibitors used were different as were the cell lines and animal models, all of which could account for different findings regarding Erk1/2 phosphorylation. Other studies, in addition to ours, have reported that inhibiting PI3K results in no change, or in some cases, a reduction in Erk1/2 signaling (Wells et al., 2007) . As well as differences in cellular characteristics, different pharmacological agents possess varying activity against the different class 1A p110 isoforms of PI3K. Although in breast cancer, the PI3KCA gene that encodes for the p110a is the most commonly mutated of the three class 1A isoforms (p110a, p110b and p110d), evidence from other cell lines show that inhibiting two of these three isoforms is insufficient to inhibit cell proliferation and survival (Foukas et al., 2010) . Therefore, PI3K inhibitors that preferentially target p110a (GDC-0941 and PIK90) may not be as effective at preventing cellular proliferation and cell cycle progression as pan class 1A inhibitors, such as NVP-BKM120 and XL147.
The more pronounced glucose and insulin derangements in the WT and MKR mice treated with the PI3K inhibitor NVP-BKM120, may be the result of more pronounced PI3K and Akt inhibition with this compound than with the dual PI3K/mTOR inhibitor NVP-BEZ235. Our protein analysis demonstrated that the inhibition of Akt phosphorylation with NVP-BEZ235 was less marked than with the PI3K inhibitor NVP-BKM120. Similar findings regarding Akt phosphorylation have previously been reported, and other studies have demonstrated an increase in Akt phosphorylation at lower doses of NVP-BEZ235 (Serra et al., 2008 (Serra et al., , 2011 . At low concentrations, NVP-BEZ235 predominantly inhibits mTORC1 activity, whereas at higher concentrations it inhibits PI3K and mTORC1/2. Therefore, in our study, the disproportionately greater suppression of S6rp phosphorylation, compared with Akt phosphorylation in NVP-BEZ235-treated tumors, may be the result of the different inhibitory concentration of NVP-BEZ235 on mTOR and Akt.
Insulin signaling is important for glucose uptake into skeletal muscle and adipose tissue by the glucose transporter GLUT4. Previous studies have demonstrated that inhibiting PI3K with wortmannin and LY294002 prevents the translocation of GLUT4 to the cell surface and glucose uptake into cells. Akt and atypical protein kinase C z are important downstream targets of PI3K that mediate this glucose uptake (Liu et al., 2006) . Inhibitors of Akt have also been reported to cause hyperglycemia by GLUT4-dependent and independent mechanisms (Tan et al., 2010) . Only very low levels of Akt appear to be necessary to maintain GLUT4 function in certain cells, suggesting alternative unknown mechanisms are also in play (Tan et al., 2010) . The difference in Akt inhibition between NVP-BKM120 compared with NVP-BEZ235 may partly explain the more dramatic hyperglycemia that was observed with NVP-BKM120. Some studies using PI3K inhibitors have not reported dramatic hyperglycemia, an affect that may be related to the p110 isoform of PI3K that is inhibited: a pan class IA inhibitor may lead to more severe glucose derangement than a selective p110a inhibitor, although the roles that the different p110 isoforms play in the metabolic effects of insulin remain to be determined (Jia et al., 2008; Sopasakis et al., 2010) .
In addition to more severe hyperglycemia, we noted more dramatic hyperinsulinemia with the PI3K inhibitor compared with the dual PI3K/mTOR inhibitor, which caused greater hyperinsulinemia than rapamycin . Inhibition of PI3K and Akt will directly lead to insulin resistance by preventing signal transduction through this pathway. Inhibiting mTOR in addition to PI3K may in fact improve insulin sensitivity, as the mTOR/S6 Kinase pathway causes serine phosphorylation of insulin receptor substrate-1, which PI3K blockade reduces insulin induced tumor growth EJ Gallagher et al attenuates signaling. Therefore, inhibiting mTOR/S6 Kinase activity may reduce some of the insulin resistance caused by PI3K inhibition by relieving the inhibition of serine phosphosylation of insulin receptor substrate-1, allowing tyrosine phosphorylation of insulin receptor substrate-1 and activation of the insulin signaling pathway (Um et al., 2006) . In conclusion, our study demonstrates that PI3K inhibitors reduce tumor growth in an animal model of insulin resistance and hyperinsulinemia. These results may be particularly relevant in individuals with insulin resistance, the metabolic syndrome and T2DM, who may have dysregulation of the PI3K pathway in breast cancer, as demonstrated in our mouse model. In our model, we demonstrate that with pan class 1 PI3K inhibition, there is no increase in activation of Erk1/2 signaling. Our data demonstrates a similar reduction in tumor growth with the dual PI3K/mTOR inhibitor and PI3K inhibition alone. However, dual inhibition of PI3K and mTOR importantly led to less severe hyperglycemia and hyperinsulinemia, which may be due to either less potent inhibition of Akt by NVP-BEZ235 or due to a reduction in insulin resistance by inhibiting mTOR. Based on the results of our study and other similar studies, many questions regarding the role of PI3K in tumor growth and metabolism have emerged. Future studies are needed to address the roles of hyperinsulinemia and diabetes in breast cancer mortality in women (Peairs et al., 2011) . Understanding more about the specific p110 isoforms in tumor growth and metabolism is necessary so that targeted therapy can lead to maximal tumor inhibition with minimal adverse metabolic consequences. This is particularly important as the PI3K/Akt/mTOR signaling pathway may be an important target in hyperinsulinemic women with breast cancer.
Materials and methods
Animals
The mice used in this study were all on the FVB/N background. WT FVB/N mice and MKR mice that have been characterized previously were used (Fernandez et al., 2001; Novosyadlyy et al., 2010) . The mice were kept on a 12-h light/ dark cycle, had free access to a standard mouse chow (Picolab rodent diet 5053; LabDiet, St Louis, MO, USA) and fresh water ad libitum. The Mount Sinai School of Medicine AAALAC-accredited animal facility provided animal care and maintenance.
Orthotopic tumor models Met-1 mammary tumor cells were initially derived from MMTV-Polyoma Virus middle T antigen (FVB/N) transgenic mice (Borowsky et al., 2005) , and MCNeuA mammary tumor cells were derived from MMTV-Neu (FVB/N) transgenic mice, the rodent equivalent of the human ERBB2 gene (Campbell et al., 2002) . Cell culture, preparation and injection were performed as described previously Novosyadlyy et al., 2010) . Tumor cells were inoculated into the fourth mammary fat pad of 8-10-week-old female virgin homozygous MKR and WT FVB/N mice. Two weeks after Met-1 cell and 3 weeks after MCNeuA cell inoculation, tumors were matched according to size between groups, and mice were treated with either the pan-class I PI3K inhibitor NVP-BKM120 (50 mg/kg body weight per day by oral gavage) dissolved in 1-methyl-2-pyrrolidone (NMP, Sigma-Aldrich, St Louis, MO, USA) and PEG300 (Sigma-Aldrich) to a ratio of 10% NMP: 90% PEG300, or the vehicle (10% NMP: 90% PEG 300). Similarly, treatment with the dual PI3K and mTOR inhibitor, NVP-BEZ235 (40 mg tosylate salt/kg body weight per day by oral gavage) dissolved in NMP and mixed in PEG300 (10% NMP: 90% PEG300) or vehicle (10% NMP: 90% PEG300), began 2 and 3 weeks after Met-1 and MCNeuA inoculation, respectively. Treatment continued in all groups for 14 days. Before and during treatment, tumor growth was measured in three dimensions (cranio-caudal, transverse and antero-posterior) using calipers. Tumor volume was calculated by the formula: 4/3 Â p Â r 1 Â r 2 Â r 3 (r ¼ radius). At the end of the study, mice were sacrificed, and tumors were removed and weighed. NVP-BKM120 and NVP-BEZ235 were obtained free of charge through material transfer agreements with Novartis Pharma (Basel, Switzerland).
Protein extraction and western blot analysis
Protein extraction and western blot analysis were performed as previously described Novosyadlyy et al., 2010) . Phospho (Ser235/236) and total S6rp, phospho (Ser473) and total Akt, phospho (Thr202/Tyr204) and total p44/42 MAPK (Erk1/2) and Bcl-2 were purchased from Cell Signaling Technology (Danvers, MA, USA). The anti-b-actin antibody was purchased from Sigma-Aldrich. Densitometric analysis was performed using ImageJ V1.44 software (National Institutes of Health, Bethesda, MD, USA).
Immunofluorescence
To quantify BrdU incorporation (as detected by immunofluorescence), MKR and WT FVB/N mice were injected intraperitoneally with BrdU (Sigma-Aldrich) at 10 ml/g of body weight, 2 h before killing of mice. Glands were fixed in 4% paraformaldehyde and embedded in paraffin. Sections were deparaffinized, rehydrated and subjected to antigen retrieval, as previously described (Cannata et al., 2010) . A mouse monoclonal antibody against BrdU (IIB5; 1:250; Santa Cruz Biotechnology, Santa Cruz, CA, USA) was used. Immunofluorescence staining was detected by incubation with secondary AlexaFluor 488-conjugated (green) goat anti-mouse IgG (1:500; Invitrogen, Eugene, OR, USA) for 2 h. Nuclei were counterstained with (4 0 ,6-diamidino-2-phenylindole) DAPI (0.2 mg/ml; Sigma-Aldrich). At least twelve individual Â 40 objective fields per group were captured for counting BrdUpositive cells. The total number of DAPI-positive cells and BrdU-positive cells were counted and recorded. Results were expressed as the percent of BrdU/DAPI staining cells (Arpino et al., 2007) .
Metabolic assays
Blood glucose levels were checked weekly with an automated glucometer (Bayer Contour, Mishawaka, IN, USA). Plasma insulin levels were measured by ELISA (Mercodia AB, Upsala, Sweden). A glucose tolerance test was performed after 8 h of fasting using a glucose bolus of 1.5 g/kg body weight administered by intraperitoneal injection. Blood glucose was measured from the tail vein immediately before (time 0) and 15, 30, 60 and 120 min after glucose injection. Serum triglycerides were assayed by the triglycerides reagent set and manufacturers specifications (Pointe Scientific, Canton, MI, USA).
